Corrected: BRIEF-Basilea Pharmaceutica H1 Operating Income CHF 9.3 Million
Aug 13 (Reuters) - Basilea Pharmaceutica H1 operating expenses CHF -67 million. * H1 basic EPS CHF 1.72 * H1 net income CHF 20.7 million
Recent news on Basilea Pharmaceutica AG, Allschwil
See all newsBrief: Basilea Pharmaceutica - Strong Cresemba Sales In Europe Trigger USD 37.5 Mln Milestone Payment
Basilea seen up after raising 2026 guidance
Brief: Basilea Expects 2026 Operating Profit Of CHF 115 Mln
Brief: Basilea Reports Presentation Of New Data For Fosmanogepix, Isavuconazole And Ceftobiprole At IDWeek 2026
RCS - Accession Theraptcs. - Accession Therapeutics: Board appointments